Changes in Hong Kong stocks | Insili Smart (03696) rose more than 9% ISM8969/HT-001 has obtained NMPA clinical trial approval to be used in Parkinson's disease treatment

The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 9%. As of press release, it had risen 8.1% to HK$44.3, with a turnover of HK$541 million.

According to the news, recently, according to the official WeChat account of Insisilicon Intelligence, Insisilicon announced that ISM8969/HT-001, an innovative oral NLRP3 inhibitor jointly developed by the company and Hengtai Biotech, has obtained clinical trial approval from the China National Drug Administration (NMPA) and is intended to be used in the treatment of Parkinson's disease.

Following the announcement of the completion of the first Australian Phase I clinical participant administration in June 2026, the approval marks the official commencement of parallel clinical evaluations in China and Australia. The purpose of this clinical study was to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacokinetic (PD) characteristics of ISM8969/HT-001 in healthy participants, as well as initial efficacy in Parkinson's disease patients, and lay the foundation for its subsequent clinical development.

Earlier, in January 2026, Insilicon Smart announced that it had reached an exclusive licensing and cooperation agreement with Shenzhen Penghu Fund, a subsidiary of Fosun Health Capital, and Hygtia Therapeutics (Hygtia Therapeutics), an investment company of Fosun Pharmaceuticals, to jointly promote the global development of ISM8969/HT-001. According to the agreement, both parties hold 50% of the global interest in the project, and Insilicon Smart is entitled to receive more than HK$500 million in advance payments and milestone payments.